166 related articles for article (PubMed ID: 32441026)
1. Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation.
Anastasilakis AD; Evangelatos G; Makras P; Iliopoulos A
Endocrine; 2020 Sep; 69(3):516-518. PubMed ID: 32441026
[TBL] [Abstract][Full Text] [Related]
2. Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough.
Anastasilakis AD; Trovas G; Balanika A; Polyzos SA; Makras P; Tournis S
J Clin Densitom; 2021; 24(2):338-340. PubMed ID: 33218880
[TBL] [Abstract][Full Text] [Related]
3. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
[TBL] [Abstract][Full Text] [Related]
4. Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Osteoporos Int; 2018 Mar; 29(3):769-772. PubMed ID: 29230512
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Teriparatide for the Treatment of Multiple Spontaneous Clinical Vertebral Fractures after Discontinuation of Denosumab in a Female Patient with Rheumatoid Arthritis: A Case Report.
Mori Y; Izumiyama T; Mori N; Aizawa T
Tohoku J Exp Med; 2021 May; 254(1):57-61. PubMed ID: 34053968
[TBL] [Abstract][Full Text] [Related]
6. Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.
Clifton Goldney D; Pelegrin C; Jerkovich F; Longobardi V; Gonzalez Rodriguez E; Zanchetta MB
Osteoporos Int; 2024 Jan; 35(1):165-171. PubMed ID: 37702746
[TBL] [Abstract][Full Text] [Related]
7. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation.
Anastasilakis AD; Polyzos SA; Makras P; Trovas G; Yavropoulou MP; Tournis S
J Clin Densitom; 2021; 24(4):591-596. PubMed ID: 33541775
[TBL] [Abstract][Full Text] [Related]
9. Second rebound-associated vertebral fractures after denosumab discontinuation.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Arch Osteoporos; 2020 Jan; 15(1):7. PubMed ID: 31898803
[TBL] [Abstract][Full Text] [Related]
10. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
Popp AW; Zysset PK; Lippuner K
Osteoporos Int; 2016 May; 27(5):1917-21. PubMed ID: 26694598
[TBL] [Abstract][Full Text] [Related]
11. Stopping Denosumab.
Lamy O; Stoll D; Aubry-Rozier B; Rodriguez EG
Curr Osteoporos Rep; 2019 Feb; 17(1):8-15. PubMed ID: 30659428
[TBL] [Abstract][Full Text] [Related]
12. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
Lamy O; Fernández-Fernández E; Monjo-Henry I; Stoll D; Aubry-Rozier B; Benavent-Núñez D; Aguado P; Gonzalez-Rodriguez E
Osteoporos Int; 2019 May; 30(5):1111-1115. PubMed ID: 30613866
[TBL] [Abstract][Full Text] [Related]
13. Multiple Rebound-Associated Vertebral Fractures after Denosumab Discontinuation: Is Prompt Antiresorptive Therapy Always Recommended,Even When the Risk of Fracture Seems Low? A Case Report.
Osella G; Puglisi S; Alì A; Reimondo G; Terzolo M
Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2303-2306. PubMed ID: 34238202
[TBL] [Abstract][Full Text] [Related]
14. Rebound-associated vertebral fractures after stopping denosumab: Report of four cases.
Dupont J; Laurent MR; Dedeyne L; Luyten FP; Gielen E; Dejaeger M
Joint Bone Spine; 2020 Mar; 87(2):171-173. PubMed ID: 31369866
[No Abstract] [Full Text] [Related]
15. Clinical vertebral fractures following denosumab discontinuation.
Polyzos SA; Terpos E
Endocrine; 2016 Oct; 54(1):271-272. PubMed ID: 27393301
[No Abstract] [Full Text] [Related]
16. Rebound vertebral and non-vertebral fractures during denosumab interruption in a postmenopausal woman.
De Sousa SMC; Jesudason D
Clin Endocrinol (Oxf); 2019 Jan; 90(1):250-252. PubMed ID: 30269340
[No Abstract] [Full Text] [Related]
17. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
[TBL] [Abstract][Full Text] [Related]
18. Letter to the Editor: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Nine Clinical Cases Report.
Trovas G
J Clin Endocrinol Metab; 2017 Mar; 102(3):1086. PubMed ID: 28359104
[No Abstract] [Full Text] [Related]
19. Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib.
Binkley N; Krueger D; de Papp AE
Osteoporos Int; 2018 Apr; 29(4):999-1002. PubMed ID: 29455249
[TBL] [Abstract][Full Text] [Related]
20. [Multiple vertebral fractures after denosumab discontinuation].
Tjelum L; Eiken P
Ugeskr Laeger; 2018 Nov; 180(45):. PubMed ID: 30404716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]